Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
-
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness
-
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
-
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
-
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
-
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Visual Disturbances
-
Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
-
Opus Genetics Appoints Rob Gagnon as Chief Financial Officer